HEK293 Canis GLP-1R Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0106M | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The Glucagon-Like Peptide-1 Receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that plays a central role in glucose metabolism by mediating the effects of the incretin hormone GLP-1. GLP-1R is primarily expressed in pancreatic β-cells, as well as in the gastrointestinal tract and central nervous system. Activation of GLP-1R enhances glucose-dependent insulin secretion, inhibits glucagon release, delays gastric emptying, and promotes satiety.
Screeningbio’s Canis GLP-1R cell line stably expresses the full-length, non-tagged canis GLP-1R in HEK293 cells. Upon ligand binding, the receptor couples to Gs proteins, leading to a robust increase in intracellular cAMP levels, which can be used to evaluate GLP-1R agonist activity in functional assays.
Product Specifications
Target Type | GPCR |
Species | Canis |
HGNC Symbol | GLP-1R |
Accession Number | XM_038683407.1 |
Parental Line | HEK293 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
The glucagon-like peptide-1 receptor (GLP-1R) is a class B G-protein-coupled receptor (GPCR) that plays a central role in glucose homeostasis and energy balance. GLP-1R is primarily expressed in pancreatic β-cells, but is also found in the central nervous system, gastrointestinal tract, cardiovascular system, and kidney. Its broad tissue distribution underlies both metabolic and extra-metabolic effects.
Upon binding to its endogenous agonist GLP-1, secreted postprandially from intestinal L-cells, GLP-1R undergoes a conformational change that activates Gs proteins. This leads to stimulation of adenylate cyclase, elevation of intracellular cAMP, and downstream activation of protein kinase A (PKA) and Epac signaling pathways. In pancreatic β-cells, this signaling enhances glucose-dependent insulin secretion, suppresses glucagon release, and promotes cell survival. In the CNS, GLP-1R activation contributes to satiety, reduced food intake, and weight control, while in the cardiovascular system it has been linked to cardioprotective effects.
GLP-1R is an established therapeutic target for type 2 diabetes mellitus and obesity. GLP-1R agonists (e.g., exenatide, liraglutide, semaglutide) are widely used to improve glycemic control and induce weight loss, with additional benefits on cardiovascular outcomes. Small-molecule agonists and positive allosteric modulators are also under investigation to expand therapeutic options. Conversely, receptor antagonists such as exendin(9-39) have been used in experimental settings to probe physiological function. Because of its multifaceted role in metabolic regulation and cardiovascular health, GLP-1R continues to be a major focus in both drug discovery and translational research.